Argentina Repeals Restrictive Pharmaceutical Patent Guidelines, Sparking Industry Debate Over Generic Drug Access
Key Insights
Argentina's government repealed restrictive pharmaceutical patentability guidelines that had been in place since 2012, effective March 18, 2026, potentially improving patent protection for pharmaceutical innovations.
The previous guidelines had limited protection for various pharmaceutical inventions including formulations, polymorphs, second medical use claims, and combination therapies.
CILFA (search), representing Argentine drugmakers, opposes the repeal and warns it could enable "evergreening" patents that extend monopolies without providing therapeutic value.
Argentina's Ministry of Health, Ministry of Economy, and National Institute of Industrial Property (INPI (search)) issued Joint Resolution No. 1/2026 on March 18, 2026, formally repealing the restrictive pharmaceutical patentability guidelines that had governed patent examination for over a decade. The move represents a significant shift toward international patent standards but has sparked immediate opposition from the country's generic drug industry.
Scope of Patent Policy Changes
The repealed 2012 guidelines had imposed strict limitations on patent protection across multiple categories of pharmaceutical inventions. Previously restricted areas included pharmaceutical formulations and compositions, Markush claims, polymorphs and pseudo-polymorphs, analogous processes, prodrugs, metabolites, selection inventions, enantiomers, combinations, salts, esters and other derivatives of known substances, dosage claims, and second medical use claims.
The repeal is expected to align Argentina's patent examination practices more closely with the country's Patent Law and international norms, potentially expanding the scope of patentable pharmaceutical subject matter.
Generic Industry Pushback
CILFA (search), the chamber representing Argentine drugmakers, immediately expressed opposition to the new resolution, citing concerns about "evergreening" patent applications. According to CILFA, these patents "protect minor innovations related to already known medicines without providing therapeutic effects or any other value, except to preserve monopolies and hinder the launch of competing medicines for many years."
The organization emphasized the competitive impact of Argentina's generic and biosimilar industry, noting that since patent protection for medicines began in October 2000, the sector has "boosted competition in the market, breaking up monopolies through the launch of generic or biosimilar versions of medicines whose patents have expired."
Economic Impact of Generic Competition
CILFA (search) highlighted substantial cost savings achieved through generic and biosimilar competition, with specific examples demonstrating significant price reductions. The locally produced version of pembrolizumab (compared to MSD's Keytruda) is 60.30% cheaper, while an Argentine alternative to semaglutide (Novo Nordisk's Ozempic and Wegovy) offers 63.50% more affordability.
Additional comparisons include a local version of Biogen's nusinersen-based Spinraza that is 45% cheaper, and a local version of the triple therapy Trikafta for cystic fibrosis (search) that costs 87.90% less than the original.
The Latin American Economic Research Foundation (FIEL) estimated that savings generated by generic and biosimilar drug launches reached $2.2 billion annually at September 2024 prices. Including additional launches and molecules not covered in the FIEL study, CILFA (search) estimates total savings could reach approximately $3.32 billion by 2025.
Market Penetration and Access
CILFA (search) noted that dozens of generic and biosimilar medications of Argentine origin are available, including flagship drugs such as rituximab, bevacizumab, sofosbuvir, filgrastim, and adalimumab. Some of these products have been on the market for over 10 years and have achieved market shares exceeding 90%, with some approaching 100% market penetration.
Enforcement Limitations
The new resolution appears to include potential limitations on enforcement. Recent commentary suggests the framework may provide a safe harbor for pharmaceutical products already on the market that could infringe patents granted under the updated system, potentially limiting enforcement options and compensation availability. However, it remains unclear whether this exception will apply to new infringing products or whether innovators will be able to pursue infringement actions under the revised regime.
Industry Response and Future Outlook
CILFA (search) emphasized its trust in the INPI (search)'s technical capacity under current leadership by Carlos Gallo to "continue conducting patentability analyses rigorously and on a scientific basis." The organization stressed that the INPI should "grant patent status only to genuine pharmaceutical innovations and should reject evergreening patents."
The chamber also acknowledged the Argentine government's decision to exclude test data protection and patent term extensions from the recent Reciprocal Trade and Investment Agreement with the United States, viewing these exclusions as supporting a "pro-competitive pharmaceutical ecosystem."
Companies with pending or contemplated Argentine patent filings in pharmaceutical, chemical, and life sciences sectors are advised to review their portfolios in light of these changes, as applications previously facing narrow examination positions may warrant renewed prosecution strategies.